RA Capital Healthcare Fund LP
Director at Tyra Biosciences; 10% owner at Hemab Therapeutics Holdings; Director at Cytek Biosciences.
- Rank
- 726th of 809
- Companies held
- 1
- Largest holding
- ARTV, 100.0% of total
- Latest SEC filing
- Aug 24, 2026
- Listed but not counted
- $1.73B
What the $66.4M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Artiva Biotherapeutics ARTV Common Stock | Indirectly (see filing footnote) | 17,329,570 | $3.83 | $66.4M | 100.0% | Form 4, Jul 31, 2026 |
Share counts are the amounts RA Capital Healthcare Fund LP reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Reported but not counted
These shares appear on RA Capital Healthcare Fund LP's filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.
| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Hemab Therapeutics Holdings COAG Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 6,372,170 | $39.86 | $254M | — | Form 4, May 12, 2026 |
| Tyra Biosciences TYRA Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 10,096,004 | $19.73 | $199M | — | Form 4, Jun 9, 2025 |
| Tyra Biosciences TYRA Common Stock | Through RA Capital Healthcare Fund, L.P. Held by a company or fund the insider manages | 8,697,956 | $19.73 | $172M | — | Form 4, Nov 8, 2024 |
| Enliven Therapeutics ELVN Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 3,220,825 | $46.41 | $149M | — | Form 4, Oct 24, 2022 |
| Janux Therapeutics JANX Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 10,141,287 | $10.29 | $104M | — | Form 4, Jun 11, 2025 |
| Cytek Biosciences CTKB Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 13,381,054 | $6.32 | $84.6M | — | Form 4, Mar 15, 2022 |
| Vor Biopharma VOR Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 4,501,882 | $18.52 | $83.4M | — | Form 4, Aug 24, 2026 |
| Mineralys Therapeutics MLYS Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 5,825,521 | $14.16 | $82.5M | — | Form 4, Mar 30, 2026 |
| Solid Biosciences SLDB Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 11,897,896 | $6.44 | $76.6M | — | Form 3, Jun 22, 2026 |
| PepGen PEPG Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 18,554,273 | $3.93 | $72.9M | — | Form 4, Sep 26, 2025 |
| Cytek Biosciences CTKB Common Stock | Through RA Capital Healthcare Fund, L.P. Held by a company or fund the insider manages | 11,082,163 | $6.32 | $70.0M | — | Form 4, Feb 28, 2022 |
| SpyGlass Pharma SGP Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 2,054,678 | $30.78 | $63.2M | — | Form 4, Feb 9, 2026 |
| Hemab Therapeutics Holdings COAG Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 1,009,052 | $39.86 | $40.2M | — | Form 4, May 12, 2026 |
| Inhibikase Therapeutics IKT Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 25,000,000 | $1.30 | $32.5M | — | Form 3, Jul 10, 2026 |
| Climb Bio CLYM Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 3,403,429 | $9.28 | $31.6M | — | Form 4, Jan 5, 2026 |
| ARS Pharmaceuticals SPRY Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 8,556,774 | $3.36 | $28.8M | — | Form 4, Sep 21, 2023 |
| ARS Pharmaceuticals SPRY Common Stock | Through RA Capital Healthcare Fund, L.P. Held by a company or fund the insider manages | 8,365,465 | $3.36 | $28.1M | — | Form 4, Sep 21, 2023 |
| Mineralys Therapeutics MLYS Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 1,867,229 | $14.16 | $26.4M | — | Form 4, Mar 27, 2026 |
| Fulcrum Therapeutics FULC Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 6,053,960 | $3.71 | $22.5M | — | Form 4, Dec 8, 2025 |
| Evommune EVMN Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 2,710,293 | $7.24 | $19.6M | — | Form 4, Feb 17, 2026 |
| Hemab Therapeutics Holdings COAG Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 354,938 | $39.86 | $14.1M | — | Form 4, May 12, 2026 |
| Acrivon Therapeutics ACRV Common Stock | Through RA Capital Healthcare Fund, L.P. Held by a company or fund the insider manages | 7,914,206 | $1.40 | $11.1M | — | Form 4, Apr 11, 2024 |
| Janux Therapeutics JANX Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 1,048,406 | $10.29 | $10.8M | — | Form 4, Jun 11, 2025 |
| Inhibikase Therapeutics IKT Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 6,970,000 | $1.30 | $9.1M | — | Form 4, Jul 29, 2026 |
| Tyra Biosciences TYRA Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 442,721 | $19.73 | $8.7M | — | Form 4, Nov 8, 2024 |
| Freenome FRNM Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 750,000 | $9.93 | $7.4M | — | Form 3, Jul 20, 2026 |
| Evommune EVMN Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 784,345 | $7.24 | $5.7M | — | Form 4, Feb 17, 2026 |
| Werewolf Therapeutics HOWL Common Stock | Through RA Capital Healthcare Fund, L.P. Held by a company or fund the insider manages | 5,076,685 | $0.99 | $5.0M | — | Form 4, Jun 11, 2026 |
| ARS Pharmaceuticals SPRY Common Stock | Through RA Capital Nexus Fund II, L.P. Held by a company or fund the insider manages | 902,904 | $3.36 | $3.0M | — | Form 4, Nov 8, 2022 |
| Adicet Bio ACET Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 1,182,624 | $2.46 | $2.9M | — | Form 4, Feb 20, 2026 |
| Adicet Bio ACET Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 959,028 | $2.46 | $2.4M | — | Form 3, Feb 17, 2026 |
| AN2 Therapeutics ANTX Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 300,853 | $5.22 | $1.6M | — | Form 4, Aug 9, 2024 |
| PepGen PEPG Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 207,672 | $3.93 | $816K | — | Form 4, Sep 26, 2025 |
| Solid Biosciences SLDB Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 109,661 | $6.44 | $706K | — | Form 3, Jun 22, 2026 |
| Acrivon Therapeutics ACRV Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 426,302 | $1.40 | $597K | — | Form 4, Apr 11, 2024 |
| Jade Biosciences JBIO Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 36,796 split-adjusted | $15.06 | $554K | — | Form 4, Apr 28, 2025 |
| Werewolf Therapeutics HOWL Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 361,229 | $0.99 | $356K | — | Form 4, Jun 11, 2026 |
| Acumen Pharmaceuticals ABOS Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 1,300,034 | $0.19 | $251K | — | Form 4, Jun 4, 2025 |
| Solid Biosciences SLDB Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 28,569 | $6.44 | $184K | — | Form 3, Jun 22, 2026 |
| Acumen Pharmaceuticals ABOS Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 588,850 | $0.19 | $114K | — | Form 4, Jun 4, 2025 |
| Mineralys Therapeutics MLYS Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 6,200 | $14.16 | $88K | — | Form 4, Feb 19, 2026 |
| Wave Life Sciences WVE Ordinary Shares | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 28,815 | $2.72 | $78K | — | Form 4, Aug 11, 2025 |
| Janux Therapeutics JANX Common Stock | Indirectly (see filing footnote) Held by a company or fund the insider manages | 6,250 | $10.29 | $64K | — | Form 4, Jun 11, 2025 |
| Vor Biopharma VOR Common Stock | Indirectly (see filing footnote) Held by a company or fund the insider manages | 1,500 | $18.52 | $28K | — | Form 4, Aug 24, 2026 |
| Jade Biosciences JBIO Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 806 split-adjusted | $15.06 | $12K | — | Form 4, Apr 28, 2025 |
| Jade Biosciences JBIO Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 254 split-adjusted | $15.06 | $4K | — | Form 4, Apr 28, 2025 |
| Acumen Pharmaceuticals ABOS Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 12,800 | $0.19 | $2K | — | Form 4, Jun 4, 2025 |
| KALA BIO KALA Common Stock | Through RA Capital Management GP, LLC Held by a company or fund the insider manages | 94 split-adjusted | $3.02 | $283 | — | Form 4, May 26, 2022 |
Open-market trades, last 12 months
| Date | Trade | Company | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 31, 2026 | Bought | ARTV | 24,944 | $9.93 | $248K | View |
| Jul 29, 2026 | Bought | ARTV | 20,824 | $9.99 | $208K | View |
| Jul 17, 2026 | Bought | ARTV | 7,882 | $8.95 | $71K | View |
| Jul 16, 2026 | Bought | ARTV | 152,472 | $8.93 | $1.4M | View |
| Jun 11, 2026 | Sold | HOWL | 17,437 | $0.38 | $7K | View |
| Jun 11, 2026 | Sold | HOWL | 245,066 | $0.38 | $93K | View |
| Jun 10, 2026 | Sold | HOWL | 42,872 | $0.37 | $16K | View |
| Jun 10, 2026 | Sold | HOWL | 3,051 | $0.37 | $1K | View |
| Jun 9, 2026 | Sold | HOWL | 345,235 | $0.37 | $128K | View |
| Jun 9, 2026 | Sold | HOWL | 24,565 | $0.37 | $9K | View |
| May 12, 2026 | Bought | COAG | 6,387 | $24.90 | $159K | View |
| May 11, 2026 | Bought | COAG | 25,720 | $25.00 | $643K | View |
| May 11, 2026 | Bought | COAG | 14,149 | $24.47 | $346K | View |
| May 8, 2026 | Bought | COAG | 1,483 | $24.98 | $37K | View |
| May 7, 2026 | Bought | COAG | 1,985 | $24.95 | $50K | View |
| May 7, 2026 | Bought | COAG | 7,921 | $24.34 | $193K | View |
| May 6, 2026 | Bought | COAG | 53,407 | $24.83 | $1.3M | View |
| May 6, 2026 | Bought | COAG | 14,611 | $23.77 | $347K | View |
| May 5, 2026 | Bought | COAG | 10,268 | $25.00 | $257K | View |
| May 5, 2026 | Bought | COAG | 87,143 | $24.59 | $2.1M | View |
| May 4, 2026 | Bought | COAG | 133,750 | $18.00 | $2.4M | View |
| May 4, 2026 | Bought | COAG | 2,541,250 | $18.00 | $45.7M | View |
| Apr 10, 2026 | Sold | VOR | 828 | $15.75 | $13K | View |
| Apr 9, 2026 | Sold | VOR | 135,201 | $16.59 | $2.2M | View |
| Apr 8, 2026 | Sold | VOR | 130,862 | $16.91 | $2.2M | View |
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 723 | Drugs Made In America Acquisition II LLC 10% owner, Drugs Made In America Acquisition II | $68.8M |
| 724 | BRC Group Holdings, Inc. 10% owner, Babcock & Wilcox Enterprises | $67.9M |
| 725 | Bpifrance Investissement S.A.S. Director, Pasqal Holding SA | $66.4M |
| 726 | RA Capital Healthcare Fund LP Director, Tyra Biosciences | $66.4M |
| 727 | Alyeska Investment Group, L.P. 10% owner, FrontView REIT | $66.3M |
| 728 | Pioneer Acquisition 1 Sponsor Holdco LLC 10% owner, Pioneer Acquisition I | $65.9M |
| 729 | Rosalind Advisors, Inc. Director, Delcath Systems | $65.2M |
Other Tyra Biosciences insiders
All TYRA insiders- Todd Harris$28.4MPresident and CEO. #3963 overall
- Robert L. Hudkins$5.4MChief Technology Officer. #13725 overall
- Ronald Swanson V.$5.4MChief Scientific Officer. #13736 overall
Questions
How much stock does RA Capital Healthcare Fund LP own?
RA Capital Healthcare Fund LP holds $66,372,253 in listed stock based on SEC filings and current prices, mostly Artiva Biotherapeutics (ARTV). That ranks 726th on the Stock Rich List.
Is this RA Capital Healthcare Fund LP's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did RA Capital Healthcare Fund LP last buy or sell stock?
The most recent open-market trade on file is a purchase of 24,944 ARTV shares on Jul 31, 2026 at $9.93.
Files jointly with SEC filer 1384859, SEC filer 1619841.